Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies

Mol Carcinog. 2022 Feb;61(2):239-242. doi: 10.1002/mc.23373. Epub 2021 Nov 18.

Abstract

Combined TGFβ/PD-L1 inhibition is currently undergoing clinical trials in multiple cancer types. The early reported clinical trials of bintrafusp alfa, a bifunctional fusion protein targeting both of these pathways, have had mixed results. Here, we briefly review recent preclinical advances that can be used to refine these ongoing clinical trials and improve their outcomes.

Keywords: PD-L1 immune checkpoint blockade; TGFβ inhibition; clinical trials; immunotherapy; squamous cell carcinoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • B7-H1 Antigen* / metabolism
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy
  • Longitudinal Studies
  • Neoplasms* / drug therapy
  • Transforming Growth Factor beta / metabolism

Substances

  • B7-H1 Antigen
  • Transforming Growth Factor beta